Algert Global’s Biolase, Inc. BIOL Stock Holding History

Algert Global’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7	Closed	-$13K	–	1092
2021 Q2	$13K	Buy	+7	New	+$13K	﹤0.01%	415

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's BIOL Position: Q3 2021 in Review

Algert Global sold out of Biolase, Inc. (BIOL) in Q3 2021, closing a stake of 7 shares — an estimated $13K sold.

Algert Global first reported a position in BIOL in Q2 2021 and held it in 1 quarter. The position peaked at $13K in Q2 2021. 38 funds tracked by Wall St. Rank hold BIOL as of Q3 2021.

Algert Global reported no remaining Biolase, Inc. position as of Q3 2021 after selling out during the quarter.
Algert Global sold 7 Biolase, Inc. shares in Q3 2021, an estimated $13K.
Algert Global first reported a position in Biolase, Inc. in Q2 2021 and held it in 1 quarter.
Algert Global's Biolase, Inc. position peaked at $13K in Q2 2021.
38 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2021.

Based on Algert Global's 13F filing for Q3 2021, filed 15 Nov 2021.